These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 27642611)
1. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Mudher Mikhael E J Diabetes Res; 2016; 2016():6962574. PubMed ID: 27642611 [TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis. Gray LJ; Dales J; Brady EM; Khunti K; Hanif W; Davies MJ Diabetes Obes Metab; 2015 Jul; 17(7):639-48. PubMed ID: 25777247 [TBL] [Abstract][Full Text] [Related]
3. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Mikhail N Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986 [TBL] [Abstract][Full Text] [Related]
4. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223 [TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Fakhoury WK; Lereun C; Wright D Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619 [TBL] [Abstract][Full Text] [Related]
6. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882 [TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Hemmingsen B; Sonne DP; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279 [TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Hassanein M; Abdallah K; Schweizer A Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915 [TBL] [Abstract][Full Text] [Related]
9. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature]. Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy. Takayanagi R; Uchida T; Kimura K; Yamada Y Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477 [TBL] [Abstract][Full Text] [Related]
11. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916 [TBL] [Abstract][Full Text] [Related]
12. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L; Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980 [TBL] [Abstract][Full Text] [Related]
13. [New concepts in the treatment of type 2 diabetes]. Meier JJ; Schmidt WE; Klein HH Internist (Berl); 2007 Jul; 48(7):698, 700-7. PubMed ID: 17541529 [TBL] [Abstract][Full Text] [Related]
14. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Ahrén B Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966 [TBL] [Abstract][Full Text] [Related]
15. Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus. Raza H; Bhutta ME; Siddique MH Sultan Qaboos Univ Med J; 2024 Aug; 24(3):418-419. PubMed ID: 39234328 [No Abstract] [Full Text] [Related]
16. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial. Göke R; Eschenbach P; Dütting ED Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473 [TBL] [Abstract][Full Text] [Related]
17. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Schweizer A; Foley JE; Kothny W; Ahrén B Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062 [TBL] [Abstract][Full Text] [Related]
18. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ; Nauck MA Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089 [TBL] [Abstract][Full Text] [Related]